GleamWall
中文EN

ALNY ALNYLAM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1178670 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY65.2%
TTM net income YoY239.7%
TTM EPS YoY206.9%
Revenue 3-yr CAGR53.0%
Net income 3-yr CAGR—

Margins

Gross margin81.8%
Operating margin13.5%
Net margin10.5%
FCF margin11.8%
EBITDA margin15.0%

Returns

ROE90.8%
ROA8.4%
ROIC (approx.)—
Asset turnover0.81x

Leverage & solvency

Liabilities / assets84.1%
Debt / equity0.00x
Current ratio2.76x
Interest coverage1.58x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026-03-312026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.46B$1.29B—$1.10B$1.25B$773.69M$594.19M$593.17M
Cost of revenue$361.75M$298.26M—$267.72M$197.23M$142.03M$70.18M$102.65M
Gross profit$1.10B$992.69M—$829.31M$1.05B$631.66M$524.01M$490.52M
R&D expense$408.54M$413.13M—$372.22M$358.81M$323.62M$265.12M$300.17M
SG&A expense$342.00M$347.92M—$325.37M$322.08M$323.31M$239.95M$295.34M
Operating income$345.80M$231.44M—$131.72M$367.98M-$16.20M$18.08M-$105.16M
Interest expense$84.37M$82.05M—$129.34M$67.46M$61.46M$58.31M$38.97M
Pretax income$295.81M$177.81M—$86.26M$280.57M-$41.31M-$2.37M-$193.96M
Income tax-$1.87B$13.31M—-$25.28M-$12.12M$30.92M$15.88M-$110.19M
Net income$2.17B$164.49M$205.99M$186.42M$292.68M-$72.23M-$18.25M-$83.76M
EBITDA$360.27M——$145.22M$381.79M-$2.25M$32.48M-$90.99M
EPS (basic)16.191.23——2.23-0.55-0.14—
EPS (diluted)15.721.21——2.14-0.55-0.14—
Weighted avg. shares (diluted)138.04M138.28M——137.35M130.63M129.68M—
Balance sheet
Cash & equivalents$1.75B$1.71B—$1.66B$1.49B$1.11B$1.02B$968.65M
Short-term investments$1.83B$1.60B—$1.25B$1.23B$1.74B$1.61B$1.72B
Receivables$1.08B$912.74M—$777.57M$964.77M$567.11M$418.04M$405.31M
Inventory$105.91M$97.11M—$82.72M$75.38M$71.69M$65.58M$78.51M
Current assets$5.11B$4.62B—$4.05B$3.95B$3.64B$3.27B$3.30B
PP&E, net$614.91M$554.14M—$513.15M$501.75M$499.79M$498.68M$502.78M
Total assets$7.99B$5.56B—$4.97B$4.85B$4.57B$4.21B$4.24B
Current liabilities$2.06B$1.51B—$1.47B$1.56B$1.30B$1.08B$1.19B
Total liabilities$4.39B$4.20B—$4.18B$4.62B$4.32B$4.10B$4.17B
Shareholders' equity$3.60B$1.35B$1.08B$789.18M$580.25M$555.35M$426.14M$67.09M
Shares outstanding133.88M133.73M—132.38M131.79M130.98M130.31M129.29M
Cash flow statement
Operating cash flow$340.99M——$163.56M$296.86M$153.73M-$118.31M-$94.66M
Capital expenditure$69.83M——$23.29M$12.14M$14.29M$8.97M$9.09M
Free cash flow$271.15M——$140.26M$284.71M$139.44M-$127.28M-$103.76M
Investing cash flow-$311.74M——-$37.17M$501.11M-$141.38M$113.77M-$52.91M
Financing cash flow$18.35M——$45.32M-$420.09M$53.76M$44.08M$31.00M
Depreciation & amortization$14.48M——$13.51M$13.80M$13.94M$14.40M$14.17M
Stock-based compensation$79.12M$86.62M—$71.63M$108.21M$111.68M$56.71M$91.64M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.